Peptides for Women
The peptides people most often research for women, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 5
- With human trials
- 1
- FDA approved (any use)
- 2
- HGHRecombinant growth hormoneHuman RCT evidence, 4 of 4Metabolism: clinical and experimental 2005, PMID 16125527Human163Animal43Summarised1FDA approved (prescription only)Overview
- SermorelinGHRH analogNo study with an outcome for womenPubMed search, 11 Oct 2026Human0Animal0Summarised0Compounded by prescriptionOverview
- TesamorelinGHRH analogNo study with an outcome for womenPubMed search, 11 Oct 2026Human0Animal0Summarised0FDA approved (Egrifta)Overview
- GHK-CuCopper tripeptideNo study with an outcome for womenPubMed search, 11 Oct 2026Human1Animal0Summarised0Injectable off Category 2 (Apr 2026)Overview
- BPC-157Gastric pentadecapeptideNo study with an outcome for womenPubMed search, 11 Oct 2026Human0Animal1Summarised0PCAC voted 8–6 for 503A (Jul 2026)Overview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What women's health covers
MedlinePlus says women have unique health issues, including pregnancy, menopause and conditions of the female organs, and that shared problems can affect women differently.[27]
What studies of the listed peptides included women
PubMed records matching the site's women-specific search (a low-specificity population search): growth hormone 163 human-only and 43 animal-only; Sermorelin 0 human-only and 0 animal-only; Tesamorelin 0 human-only and 0 animal-only; GHK-Cu 1 human-only and 0 animal-only; BPC-157 0 human-only and 1 animal-only.
Calculated from goal women; ledger date 2026-10-02; counts hgh (human only 163, animal 43, rct 55), sermorelin (human only 0, animal 0, rct 0), tesamorelin (human only 0, animal 0, rct 0), ghk-cu (human only 1, animal 0, rct 0), bpc-157 (human only 0, animal 1, rct 0). Formula: Copied from web/src/data/goals.json: peptides[].ledger.humanOnly.n and ledger.animal.n for this goal (PubMed title/abstract search, humans[mh] NOT animals vs animals NOT humans).
The one trial that explicitly enrolled women gave low-dose GH to healthy aged women and men and found it increased whole-body protein synthesis, a protein-turnover measure rather than a strength or health outcome.[1]
Sermorelin and tesamorelin have no records matching the women-specific search, so any result for them comes from men.
Calculated from goal women; counts sermorelin (human only 0, animal 0, rct 0), tesamorelin (human only 0, animal 0, rct 0). Formula: Copied from goals.json for goal 'women': peptides[].ledger.humanOnly.n, ledger.animal.n and ledger.rct.n.
Labels that name women
Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder.[28]
Novarel (hCG) lists induction of ovulation and pregnancy in anovulatory, infertile women whose anovulation is secondary rather than due to primary ovarian failure.[29]
Common questions
What are the best peptides for women?
The evidence does not rank peptides for women as a group; the only labelled peptide-type drug for women here treats a defined sexual desire disorder in premenopausal women.[28]
Has growth hormone been tested in women?
Yes, in older adults of both sexes, where low-dose GH raised whole-body protein synthesis; that does not show a clinical benefit for women.[1]
Explore nearby goals
Sources
- 1Effects of growth hormone and/or sex steroid administration on whole-body protein turnover in healthy aged women and men.Metabolism: clinical and experimental · 2005PMID 16125527Accessed 2 Oct 2026
- 2PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) (104 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (tesamorelin[tiab] OR TH9507[tiab]) AND (pharmacokinetic*[tiab] OR half-life[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: "BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab] (230 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: "BPC-157"[tiab] AND humans[mh] (52 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (patients[tiab] OR clinical trial[pt] OR randomized[tiab]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (colitis[tiab] OR inflammatory bowel[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tendon[tiab] OR ligament[tiab] OR muscle[tiab] OR bone[tiab] OR arthritis[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (nerve[tiab] OR neuropath*[tiab] OR spinal[tiab] OR liver[tiab] OR wound[tiab] OR burn[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 23PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (36 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 24PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 25PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (57 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 26PubMed search: ("BPC-157"[tiab] OR "BPC 157"[tiab]) AND (human[tiab] OR patient*[tiab] OR volunteer*[tiab]) AND (adverse[tiab] OR safety[tiab] OR "side effects"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 27Official web pageOfficial web page · web page
- 28VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 29NOVAREL ® (chorionic gonadotropin) for injection, for intramuscular use Initial U.S. Approval: 1974FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.